SAN FRANCISCO and CHICAGO, October 18, 2024 – cTRL Therapeutics, a biotechnology company advancing next-generation cell therapies for solid tumors, today announced two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024, taking place November 8-10 in Houston, TX. These presentations will highlight the therapeutic potential of circulating tumor-reactive lymphocytes (cTRLs), isolated using cTRL’s proprietary IsoQore™ platform, as a transformative new treatment modality for solid tumors.

Details of cTRL’s poster presentations at SITC are as follows:

• Title: Anti-tumor activity of circulating tumor-reactive lymphocytes (cTRLs) isolated from checkpoint-refractory melanoma patients that failed TIL manufacturing.

  • Abstract Number: 401

  • Date and Time: Friday, November 8, from 9:00 a.m. to 7:00 p.m. CST

  • Location: Exhibit Halls A & B, George R. Brown Convention Center

• Title: Circulating tumor-reactive lymphocytes (cTRLs) isolated from colorectal cancer (CRC) patients are reactive against autologous tumors and show less exhaustion than tumor-infiltrating lymphocytes (TILs).

• Abstract Number: 400

• Date and Time: Saturday, November 9, from 9:00 a.m. to 7:00 p.m. CST

• Location: Exhibit Halls A & B, George R. Brown Convention Center

About CTRL Therapeutics

cTRL Therapeutics is redefining cell therapy for solid tumors through its proprietary IsoQore™ platform, which isolates and expands circulating tumor-reactive lymphocytes (cTRLs) from peripheral blood. The company’s lead product, cTRL-001, offers a scalable and outpatient-ready solution for a broad range of solid tumors. cTRL is advancing its clinical pipeline to enhance patient access to life-saving therapies. For more information, please visit www.ctrl-tx.com.

Media Contact

Marites Coulter, Deerfield Group

marites.coulter@deerfieldgroup.com